

## **BioMimics 3D<sup>®</sup>, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration**

HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System.

The BioMimics 3D stent has a unique 3-dimensional helical shape, designed to impart natural curvature to the diseased femoropopliteal artery, promoting swirling flow and elevating wall shear, which has been proven to have an antiproliferative effect on the vessel.<sup>1</sup> The helical shape of the BioMimics 3D stent is also designed to facilitate shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression causing localized strains that in a straight stent may lead to stent fracture and chronic vascular injury.<sup>2,3</sup>

The benefits of the BioMimics 3D stent design have been well established in the MIMICS clinical research program, enrolling more than 1,750 patients worldwide. In the most recent findings presented this April by Dr. Michael Lichtenberg (Chief Physician Arnsberg Vascular Center, Arnsberg, Germany) at CX 2022 Live, BioMimics 3D showed impressive durability with a 71% primary patency and a 78% Freedom From CDTLR in a challenging, real-world patient population.

“Veryan Medical is thrilled to announce a collaboration with Premier, a globally recognized leader in healthcare, for the nationwide distribution of the BioMimics 3D stent platform” said Veryan Medical CEO, Nick Yeo. “This is a significant milestone for our organization as we look to expand our ability to transform the lives of patients with peripheral vascular disease.”

Premier is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and 225,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost.

### **About Veryan Medical**

Veryan Medical is an Otsuka Medical Devices company which is a division of Otsuka Holdings, a leading global healthcare group with operations in pharmaceuticals, nutraceuticals and medical devices generating annual worldwide sales of more than \$13B. Veryan is focused on developing innovative devices for use in peripheral interventional procedures. The BioMimics 3D<sup>®</sup> Vascular Stent system is intended for the treatment of peripheral arterial disease (PAD) in the femoropopliteal arteries. PAD affects 12-14% of the general population<sup>4</sup>- and impacts the quality of life of many. Critical limb threatening ischemia (CLTI) patients in particular experience

2440 Research Boulevard, Suite 200, Rockville, MD 20850, USA

**t: +44 (0)1403 258984 | e: [info@veryanmed.com](mailto:info@veryanmed.com) | [www.veryanmed.com](http://www.veryanmed.com)**

high amputation and mortality rates.<sup>5</sup> The cost burden on healthcare systems is significant and of particular concern are the revascularization rates up to 90 days post-intervention due to the use of sub-optimal therapies.<sup>6</sup>

## CONTACT

Joe DeJohn  
Chief Commercial Officer  
Joe.DeJohn@VeryanMed.com

## REFERENCES

1. Caro et al. 2013 J R Soc Interface 10: 20130578
2. BH Smouse et al, Endovasc. Today, vol 4, no. 6, pp. 60-66, 2005
3. Scheinert D et al, J Am Coll Cardiol 2005;45:312-5
4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994028/>
5. Duff S, Mafilios MS, Bhounsule P, Hasegawa JT. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187–208. doi: 10.2147/VHRM.S209241.
6. Secemsky EA, Schermerhorn M, Carroll BJ, et al. Ann Intern Med 2018;168:93-9